April 12, 2022
Financial Times — April 12, 2022. “There is now growing — if still grossly inadequate — attention being paid to preventing resistance and developing new drugs. But the international response has largely ignored the matter of access to them, to the detriment of immediate health needs and the long-term effort to curb drug-resistant infections,” Ramanan Laxminarayan, founder and director of the One Health Trust in Washington, a senior research scholar at Princeton University, and board chair at the Global Antibiotic Research & Development Partnership in Geneva.
